New drug combo for untreated advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new targeted drug (emavusertib) combined with standard chemotherapy and immunotherapy for people with advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic bile duct or gallbladder cancer that hasn't been treated with systemic therapy.
- You are at least 18 years old and able to care for yourself (ECOG score 0-2).
- Your blood counts and organ function are within certain limits (see your doctor for details).
- You have not had other cancer treatments besides certain prior chemo or immunotherapy completed more than 6 months ago.
- You are willing to use effective birth control during and for a period after treatment.
- You can swallow pills and have no condition that would prevent absorbing the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CTX-009 combined with three standard chemotherapy drugs (gemcitabine, cisplatin, and durvalumab) as a first treatment for bile duct cancer that cannot be removed by surgery or has spread. It aims to see if this combination is safe and effective.
This study tests a combination of two chemotherapy drugs (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab), alternating with a targeted therapy (pemigatinib) for people with advanced biliary tract cancer that has an FGFR2 gene change. The goal is to see if this treatment sequence helps control the cancer.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial tests a new immunotherapy drug combined with standard chemotherapy as a first treatment for advanced bile duct or gallbladder cancer. It may help your immune system fight the cancer while chemotherapy attacks the tumor directly.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
Hear when a new Metastatic Biliary Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.